DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kaletra (Lopinavir / Ritonavir) - Current Clinical Trials


Kaletra Related Clinical Trials

A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort [Completed]

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients [Completed]

Lopinavir Capsules to Kaletra or Invirase Tablets [Recruiting]

Kaletra: Therapy With Double Protease Inhibitors [Recruiting]

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients [Terminated]

KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) [Recruiting]

Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children [Recruiting]

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) [Recruiting]

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV co-Infected Subjects vs Baseline Liver Biopsy Metavir Score [Completed]

Kaletra Sex/Gender Pharmacokinetics (PK) Study: A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir [Recruiting]

Lopinavir/Ritonavir (Kaletra)PK [Recruiting]

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure [Recruiting]

Raltegravir Kaletra Pharmacokinetics [Completed]

A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects [Recruiting]

Kaletra and Viread in Antiretroviral Naïve Patients [Recruiting]

Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens [Completed]

Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis [Not yet recruiting]

Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients [Completed]

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines [Recruiting]

A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules [Not yet recruiting]

Lopinavir/Ritonavir Monotherapy vs Standard HAART in HIV/HCV Coinfected Patients Starting Treatment With Anti HCV Therapy [Recruiting]

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir) [Recruiting]

GW873140 In Combination With Kaletra In HIV Infected Subjects [Terminated]

Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil [Active, not recruiting]

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet [Recruiting]

Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets). [Recruiting]

GSK706769/KALETRA Drug-Drug Interaction Study [Recruiting]

Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women [Active, not recruiting]

Kaletra Monotherapy in HIV/HCV Co-Infected Subjects [Recruiting]

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy [Recruiting]

Post-Exposure Prophylaxis in Health Care Workers [Recruiting]

Kaletra-isentress Treatment Evaluation [Recruiting]

A Simplified Kaletra (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects [Completed]

Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection [Recruiting]

ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial [Recruiting]

BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects [Not yet recruiting]

Metabolic Effects of Switching Kaletra to Boosted Reyataz [Recruiting]

Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) [Recruiting]

Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients [Completed]

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV [Active, not recruiting]

Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects [Completed]

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients [Suspended]

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance [Completed]

Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients [Active, not recruiting]

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin [Recruiting]

Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily [Recruiting]

The Effect of Lopinavir/Ritonavir on Endothelial Function [Completed]

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV [Active, not recruiting]

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women [Active, not recruiting]

Prospective, Open Label and Randomized Clinical Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra vs Nevirapine in co-Infected HIV/HCV Patients [Recruiting]

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study [Recruiting]

Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children [Recruiting]

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin [Recruiting]

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment [Active, not recruiting]

Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC [Recruiting]

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease [Recruiting]

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc [Recruiting]

Raltegravir Insulin Sensitivity Study [Recruiting]

Kaletra in Combination With Antiretroviral Agents [Recruiting]

BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r) [Completed]

Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV [Recruiting]

Influence of Drug Transporter Expression on the Pharmacokinetics of the HIV Protease Inhibitor Kaletra [Recruiting]

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-Based HAART in Advanced HIV Disease [Recruiting]

Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir in HIV-Negative Healthy Subjects [Active, not recruiting]

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects [Withdrawn]

Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy [Completed]

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor [Completed]

Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART [Completed]

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen - Study A [Active, not recruiting]

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen - Study B [Active, not recruiting]

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients [Recruiting]

Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-Partum Phase. ANRS 135 Primeva [Recruiting]

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) [Recruiting]

Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir [Recruiting]

A Trial to Determine the Long-Term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence [Recruiting]

Special Investigation of Kaletra in Pregnant Women [Recruiting]

Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa [Recruiting]

Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ) + Lopinavir/Ritonavir (Kaletra ) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ). Prospective, Randomized, Open. [Not yet recruiting]

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV [Recruiting]

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) [Recruiting]

RAltegravir Switch STudy: Effects on Endothelial Recovery [Recruiting]

Atazanavir or Lopinavir in HIV Post-Exposure Prophylaxis [Not yet recruiting]

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV [Active, not recruiting]

Relationship Between HIV-1 Subtype and ARV Response [Recruiting]

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet [Recruiting]

A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome [Not yet recruiting]

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy [Recruiting]

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks [Completed]

Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir [Recruiting]

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment [Not yet recruiting]

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy [Recruiting]

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada [Active, not recruiting]

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients [Recruiting]

Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-Based Regimen [Recruiting]

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) [Recruiting]

Safety of and Immune Response to Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in Adults With Acute HIV Infection [Active, not recruiting]

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice-Daily Administration, When Co-Administered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects [Active, not recruiting]

The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-Naive HIV-1 Infected Patients [Completed]

Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure. [Completed]

Once-Daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl [Recruiting]

A Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Dosing in Antiretroviral-Experienced, HIV-1 Infected Subjects [Active, not recruiting]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015